RxDoctor Payments Data

Luisito Gonzales, MD

Cardiovascular Disease · Elkhart, INNPI 1164425997

Payments from drug & device makers

$11,410in general payments, 2019–2025

Across 682 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Merck$1K
  • Boehringer Ingelheim$953
  • Amgen$716
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$11,356100%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,410 in reported general payments places this provider in the 70th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$279,481
Medicare patients
1,545
Services billed
5,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban877$803,457
EntrestoSacubitril/Valsartan369$376,304
XareltoRivaroxaban243$271,116
JardianceEmpagliflozin215$197,236
FarxigaDapagliflozin Propanediol127$117,817
MultaqDronedarone Hcl79$97,482
BrilintaTicagrelor107$66,308
VerquvoVericiguat64$50,572
Repatha SureclickEvolocumab38$38,113
NexlizetBempedoic Acid/Ezetimibe43$21,095
Dofetilide101$15,349
Flecainide Acetate410$15,195
Praluent PenAlirocumab12$11,693
Ranolazine ErRanolazine141$10,945
Midodrine Hcl75$8,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$591$803,457877 claims
NovartisEntresto$1,159$376,304369 claims
Johnson & JohnsonXarelto$1,188$271,116243 claims
Boehringer IngelheimJardiance$953$197,236215 claims
AstraZenecaFarxiga, Brilinta$582$184,124234 claims
Sanofi-aventis U.S. LLCMultaq$222$97,48279 claims
MerckVerquvo$1,052$50,57264 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$291$29,35960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →